(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 54.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Nurix Therapeutics's revenue in 2026 is $36,766,000.On average, 16 Wall Street analysts forecast NRIX's revenue for 2026 to be $7,249,358,121, with the lowest NRIX revenue forecast at $3,396,982,048, and the highest NRIX revenue forecast at $15,255,907,401. On average, 15 Wall Street analysts forecast NRIX's revenue for 2027 to be $12,076,036,634, with the lowest NRIX revenue forecast at $3,632,981,595, and the highest NRIX revenue forecast at $25,455,571,206.
In 2028, NRIX is forecast to generate $23,130,861,507 in revenue, with the lowest revenue forecast at $3,962,488,439 and the highest revenue forecast at $42,062,716,120.